This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Amy S. Paller, MD
Department of Dermatology North Carolina Memorial Hospital Chapel Hill, NC 27514

Amy Wishner, MD; Henry H. Roenigk, Jr, MD
Northwestern University Medical Center Chicago

Arch Dermatol. 1984;120(4):438.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Meclofenamate sodium (Meclomen) is a nonsteroidal anti-inflammatory agent that has been used for the treatment of rheumatoid arthritis and osteoarthritis.¹ Its mechanism of action is believed to be the inhibition of prostaglandin synthesis. The drug causes diarrhea in up to one third of the treated patients, but its other side effects, eg, abdominal discomfort, anemia, and rashes, are rare.

The potential efficacy of meclofenamate in psoriasis was suggested by Winthrop,² who found notable regression of psoriasis within one week after he and two patients began using the drug for psoriatic arthritis. Other inhibitors of prostaglandin synthesis, tolmetin sodium³ and benoxaprofen,⁴ have been described as effective for psoriasis.

Patients and Methods.—

We performed a double-blind randomized trial of 15 patients with psoriasis alone or with psoriasis and arthritis. Patients were required to stop any systemic or topical antipsoriatic agents and phototherapy for two weeks . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?